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ABSTRACT: Expanded carrier screening (ECS) entails a screening offer for carrier status for multiple recessive disorders simultaneously
and allows testing of couples or individuals regardless of ancestry or geographic origin. Although universal ECS—referring to a screening
offer for the general population—has generated considerable ethical debate, little attention has been given to the ethics of preconception
ECS for patients applying for assisted reproduction using their own gametes. There are several reasons why it is time for a systematic
reflection on this practice. Firstly, various European fertility clinics already offer preconception ECS on a routine basis, and others are
considering such a screening offer. Professionals involved in assisted reproduction have indicated a need for ethical guidance for ECS.
Secondly, it is expected that patients seeking assisted reproduction will be particularly interested in preconception ECS, as they are
already undertaking the physical, emotional and economic burdens of such reproduction. Thirdly, an offer of preconception ECS to
patients seeking assisted reproduction raises particular ethical questions that do not arise in the context of universal ECS: the professional’s
involvement in the conception implies that both parental and professional responsibilities should be taken into account. This paper reflects
on and provides ethical guidance for a responsible implementation of preconception ECS to patients seeking assisted reproduction using
their own gametes by assessing the proportionality of such a screening offer: do the possible benefits clearly outweigh the possible harms
and disadvantages? If so, for what kinds of disorders and under what conditions?
Key words: expanded carrier screening / assisted reproduction / genetic testing / non-invasive prenatal diagnosis / ethics / proportionality /
screening offer
Introduction
Expanded carrier screening (ECS) refers to screening for multiple
(mostly) autosomal and X-linked recessive disorders at the same time
and allows testing of individuals or couples regardless of ancestry or
geographic origin. ‘Universal’ ECS—defined as a carrier screening offer
to all prospective parents, regardless of their a priori carrier risk—has
generated considerable ethical debate (Langlois et al., 2015; van der
Hout et al., 2017; Chokoshvili et al., 2018; Kraft et al., 2019).
However, little attention has been given to the ethics of ‘selective’
ECS for patients applying for assisted reproduction using only their
own gametes (the ethics of ECS in donor conception was previously
addressed by ESHRE (Dondorp et al., 2014)). There are several rea-
sons why also a systematic reflection on the ethics of ECS as offered
to patients seeking assisted reproduction using their own gametes is
urgently needed. Firstly, various European fertility clinics already
offer ECS on a routine basis (Martin et al., 2015; Abuli et al., 2016;
Gil-Arribas et al., 2016), and others are considering a similar practice.
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Professionals involved in assisted reproduction have indicated a need
for ethical guidance with regard to the option of offering ECS to
couples applying for assisted reproduction because of either subfertility
or a high genetic risk of having an affected child (personal communica-
tions). Secondly, it is expected that patients seeking assisted reproduc-
tion will be particularly interested in ECS, as they are already
undertaking the (physical, emotional and economic) burdens of IVF or
other forms of assisted reproductive technologies (ART) (Cho et al.,
2013; Franasiak et al., 2016). This may hold true especially for those
turning to assisted reproduction in order to avoid the transmission of
a known disease-causing variant to their children. As their embryos
will already be subjected to preimplantation genetic testing for mono-
genetic diseases (PGT-M)—formerly known as preimplantation genetic
diagnosis (PGD)—the option to simultaneously avoid the transmission
of other serious disorders (by adding ECS to the patients’ work-up)
may well be an appealing option. Thirdly, an offer of ECS to patients
applying for assisted reproduction raises particular ethical questions
that do not arise in the context of universal ECS: the involvement of
professionals in the conception implies that from a moral point of
view, both parental and professional responsibilities should be taken
into account.
This paper reflects on and provides ethical guidance for a responsi-
ble implementation of ECS to patients seeking assisted reproduction.
The questions to be addressed are:
Is the offer of ECS to all patients seeking assisted reproduction using their own
gametes proportionate, i.e.: do the possible benefits of such screening clearly out-
weigh the possible harms and disadvantages? If so, for what kinds of disorders
and under what conditions?
In answering these questions, we will take account of the fact that
in some countries carrier screening is already available—either on a
public or private basis—while other countries do not (yet) offer any
form of carrier screening.
This paper first sketches relevant (technological) developments in
the field of carrier screening and outlines some current ECS-in-
assisted-reproduction practices in Europe and the USA. Second, ethical
issues relevant to the implementation of ECS in assisted reproduction
will be addressed, culminating, finally, in a set of recommendations.
Although this paper concentrates on the ethics of an ECS offer to
patients applying for assisted reproduction, it should be noted that
some considerations may also have implications for the general debate
about ECS.
Before we move on, we would like to make one note of clarifica-
tion. Carrier screening can be performed in the preconception or pre-
natal period. In the context of assisted reproduction, an offer of ECS
will be in the preconception stage. To avoid any misunderstandings, in
the remainder of this document the term ‘preconception ECS’ will be
used.
All abbreviations used in the paper are listed in Table I.
Background and facts
Over the past two decades, more than 1300 recessively inherited (au-
tosomal or X-linked) disorders have been identified, with a mild to se-
vere impact on health and prospected lifespan (Henneman et al.,
2016). Carriers of autosomal recessive disorders have only one copy
of the mutated gene and usually do not show any symptoms of the
disease. However, couples that carry disease-causing variants in the
same gene on autosomes have a 1-in-4 risk with each pregnancy that
their child will inherit both mutated genes and develop the disease.
When a woman is a carrier of an X-linked disorder, her male offspring
has a 1-in-2 risk of being affected. In this paper, the term ‘carrier cou-
ple’ refers to couples of whom both partners have a so-called class 4
or 5 variant in the same autosomal recessive disease gene as well as
to couples of whom the female partner is carrier of an X-linked disor-
der. Whereas class 4 variants have a high likelihood of being patho-
genic, class 5 variants are considered to be definitely pathogenic.
In some countries, diagnostic testing for carrier status of recessive
disorders has been offered to relatives of a proband for many years,
as part of regular clinical genetics. In addition, some ethnic communi-
ties with a higher prevalence of particular recessive disorders have in-
troduced carrier screening for its members, irrespective of their family
history. Well-known examples of the so-called ‘ancestry-based carrier
screening’ are beta-thalassaemia carrier screening in several high-risk
populations in the Mediterranean region (Cousens et al., 2010) and
premarital carrier screening for recessive diseases more prevalent
among members of the Ashkenazi Jewish population, such as
TaySachs disease, Canavan disease and Bloom syndrome (Kaback,
2000; Wailoo and Pemberton, 2006). A more recent development is
the promotion of universal approaches that offer carrier screening to
Table I Abbreviations used in discussion of the ethics of
preconception expanded carrier screening in ART.
ACCE Analytic validity, clinical validity, clinical utility,
and ethical, legal, and social issues
AD Autosomal dominant
ART Assisted reproductive technologies
CF Cystic fibrosis
ECS Expanded carrier screening
FM Full mutation
FXS Fragile X syndrome
FXTAS Fragile X-associated Tremor/Ataxia Syndrome
IVF In vitro fertilization




NIPD Non-invasive prenatal diagnosis
PCS Preconception carrier screening
PGT Preimplantation genetic testing
PGT-A Preimplantation genetic testing for aneuploidy
(formerly termed preimplantation genetic
screening or PGS)
PGT-M Preimplantation genetic testing for monogenetic diseases
PM Pre-mutation
POI Premature ovarian insufficiency
SCD Sickle cell disease
VOUS Variants of unknown clinical significance
WESA/WGSA Whole exome/genome sequencing and analysis
























































































all individuals regardless of ethnicity or family history, for instance car-
rier screening for cystic fibrosis (CF) in the USA (American College of
Obstetricians and Gynecologists, 2011).
While in the past, carrier screening mainly involved a single or only
a few disease-causing variants, the availability of new genomic testing
possibilities has given carrier screening new impetus: next-generation
sequencing (NGS) technologies allow for efficient and affordable
screening of hundreds of disease-causing variants at the same time
(Grody et al., 2013). Such ECS is expected to provide valuable
information for people who do not belong to a traditional ‘high-risk’
population. Although rare individually, it is estimated that at least 1 in
100 couples of the general population are at high risk of having a child
with a serious recessive disorder (Edwards et al., 2015; Grody, 2016;
American College of Obstetricians and Gynecologists, 2017). Some
commentators, arguing that the risk of having a child affected with a
serious recessive condition could be between 0.25 and 0.5%, stipulate
that this risk is in the same order of magnitude as the risk for a
37-year-old woman of having a child with Down syndrome (Ropers,
2012).
In developed countries, recessive disorders collectively account for
20% of infant mortality and 10% of paediatric hospitalizations (Costa
et al., 1985, Kumar and Jumali, 2006). The ultimate chance of giving
birth to a live born child with a recessive disorder is a combination of
carrier risk, the risk of de novo variants in the embryos, and the poten-
tial of the affected foetus to survive to term. Carrier screening only
measures carrier risk and cannot reveal the occurrence of de novo
variants.
Carrier screening can be performed either before or during preg-
nancy. Preconception carrier screening (PCS) has the advantage of
allowing a wider range of reproductive options than only prenatal diag-
nosis followed by a possible termination of pregnancy. These choices
include gamete donation and PGT-M, opting for adoption and refrain-
ing from parenthood. However, as many pregnancies are not planned,
PCS has not been widely used in the past except by some ethnic
groups, especially Ashkenazi Jews, and in countries that have made
such screening mandatory before couples are given approval to get
married. For instance, couples in Iran, Saudi Arabia and Cyprus are le-
gally obliged to participate in premarital carrier screening for haemo-
globinopathies (Cousens et al., 2010). Since pregnant women generally
receive medical attention, some health specialists and reproductive
counsellors consider prenatal carrier screening rather than PCS the
most practical—but not necessarily the most ethical—approach
(Henneman et al., 2016).
In the context of assisted reproduction, it is much easier to reach
potentially interested couples in the preconception period. In
European countries, 2 6% of births are achieved by means of ART
(Calhaz-Jorge et al., 2017). Couples who have already undertaken the
physical, emotional and economic burdens of fertility treatment may
well be particularly positive towards carrier screening, as this can be
easily added to a planned IVF cycle and may increase the chances of
having a healthy child. As mentioned above, this applies even more to
couples who are eligible for PGT-M, whose primary concern is the
possible transmission of genetic disease to their children. Genetics pro-
fessionals from the USA who were asked to assess the potential bene-
fits and challenges of preconception ECS in reproductive healthcare,
indicated that ‘the additional demands associated with ECS and PGD
(following the identification of a shared genetic risk) would be lower
for IVF patients than for other couples’ (Cho et al., 2013) (but see
also the section ‘Proportionality’). Franasiak et al. likewise state that
‘preconception genetic testing and counselling are important for
patients undergoing infertility care. This unique population allows for
thorough counselling and the opportunity to test for a variety of inher-
itable diseases prior to conception when in vitro fertilization and pre-
implantation genetic diagnosis are used’ (Franasiak et al., 2016).
In the last few years, a number of fertility clinics in Europe started
offering preconception ECS to couples undergoing IVF or other forms
of ART (Martin et al., 2015; Abuli et al., 2016; Gil-Arribas et al., 2016).
In 2015, Martin et al. published a study in which 138 couples seeking
assisted reproduction using their own gametes were undergoing pre-
conception ECS for more than 600 disease phenotypes. Seven couples
were identified as carrier couples. These couples received genetic
counselling and were advised to opt for PGT-M. At time of writing,
four of the identified carrier couples had decided to start a PGT-M
trajectory (Martin et al., 2015). Larger follow-up studies are needed
to describe the actual uptake of PGT-M, or alternatively gamete
donation, after ECS.
Ethical reflections
When considering or providing preconception ECS to patients seeking
assisted reproduction, clinicians should always take into account the
relevant medico-legal norms in their countries’ jurisdictions. This sec-
tion concentrates on the ethics of such screening. While some of the
issues to be addressed specifically relate to preconception ECS to
patients seeking assisted reproduction, other issues are also relevant
for normative reflections on (preconception) ECS generally.
The aim of preconception ECS in assisted
reproduction: autonomy or prevention?
Until the 1980s, many health professionals considered prevention—in
the sense of reducing the birth prevalence of serious disorders—the
primary aim of reproductive screening, both during and before preg-
nancy. For instance, in an influential paper, public health epidemiolo-
gists Zena Stein and Mervyn Susser advocated prenatal diagnostic
testing and elective termination of pregnancy as preventative measures
to reduce the incidence of Down syndrome at birth (Stein and Susser,
1971; Porter, 1982). Not surprisingly, this emphasis on prevention was
soon felt to raise serious ethical concerns, especially with regard to
screening for abnormalities during pregnancy. These concerns were
2-fold. Firstly, however, much it is stressed that screening should en-
able women to make their own decisions, it is difficult to see how an
account of prenatal screening as aimed at reducing the number of chil-
dren born with the relevant conditions would not promote nudging
women into making the ‘right’, i.e. ‘preventative’, reproductive choices.
Considering the moral sensitivity and emotional impact of abortion, it
would be problematic to pressure women into terminating a desired
pregnancy. Secondly, the prevention view has invited the criticism of
disability rights’ advocates, according to whom the practice reflects a
discriminatory attitude towards people living with the relevant condi-
tions (Parens and Asch, 2000). In order to avoid these moral chal-
lenges, official (Western) accounts of the aim of prenatal screening
have moved away from the language of prevention and accepted the
























































































so-called autonomy paradigm, meaning that such screening should en-
able individual pregnant women (and their partners) to make meaning-
ful reproductive choices with regard to having or not having a child
with a serious disorder or disability (de Jong and de Wert, 2015;
Dondorp et al., 2015).
In the context of carrier screening, we can observe a more diffuse
picture regarding the primary aim of screening. In accordance with the
first prenatal screening programmes, most ancestry-based carrier
screening initiatives dating from the 1950s intended to avoid the birth
of children with serious genetic conditions. With regard to more re-
cently introduced ancestry-based carrier screening programs, the pic-
ture becomes less clear; in describing their goals, many of these
programmes include elements of both the autonomy and the preven-
tion paradigms. For instance, the Jewish Genetic Disease Consortium
describes the goal of carrier screening as ‘decreas[ing] the incidence of
Jewish genetic diseases and assure healthy families by increasing pre-
conception carrier screening rates and promoting the understanding of
reproductive options available to carrier couples’. In many Western
countries, an unambiguous embrace of the autonomy paradigm
accompanied the introduction of universal carrier screening—i.e. a tar-
geted or ECS offer to all individuals or couples of reproductive age
(Laberge et al., 2010; Edwards et al., 2015; Nazareth et al., 2015). The
goal to enable autonomous reproductive choice is, for instance,
reflected in a policy paper about ECS by the European Society of
Human Genetics (Henneman et al., 2016).
How to explain the difference between the paradigms underlying
ancestry-based and universal carrier screening? There are various rea-
sons why many stakeholders—including prospective parents—consider
‘prevention’ a justified aim of ancestry-based carrier screening. Firstly,
couples belonging to an ethnic community with a higher prevalence of
particular recessive disorders often have close experience with the dis-
tress of parents whose child is born with a genetic disease or disability;
they want to ensure that they do not suffer the same fate. Secondly, it
should be noted that many programmes aimed at prevention offer car-
rier screening before, and not during pregnancy. Apparently, a pro-
gramme’s pursuit of prevention is considered less problematic in the
preconception period. The reason for this is that before pregnancy,
carrier couples have the largest range of reproductive options at their
disposal, including gamete donation and PGT-M. Passing on a genetic
disorder to one’s offspring increasingly becomes a controllable factor
in a sense that would not entail emotional and morally highly sensitive
decision-making concerning pregnancy termination.
Parental responsibilities
Do prospective parents have a moral obligation to take preventative
measures if they have the means to avoid the conception of a severely
affected child without disproportionate cost to themselves? This ques-
tion does not only emerge in the context of ancestry-based PCS, but
may be relevant for all PCS initiatives, including preconception ECS to
patients seeking assisted reproduction.
In families without an a priori increased carrier risk, the birth of an
affected child typically comes as a surprise. Preconception ECS would
enable these families to be informed timely about their carrier risk and
reduce the chance of conceiving a child with a severe genetic disorder.
However, is it reasonable to expect that couples who do not belong
to a high-risk group participate in preconception ECS? Would it not
be more appropriate to merely inform them about possible participa-
tion in such screening and thus to increase their reproductive auton-
omy? Presenting preconception ECS as a ‘reproductive code of
conduct’ for all couples who wish to have children may be too high a
price (van der Hout et al., 2019). However, one could also argue that
the relevant responsibility of prospective parents does not (just)
depend on the magnitude of their risk of being a carrier couple, but
(also) on the severity of the disease under consideration (Clarkeburn,
2000). An in-between position, accepted in the present document,
would be that prospective parents, given their generally low a priori
risk, do not have a moral responsibility to take part in preconception
ECS, but that proven carrier couples, given their high risk, may have a
conditional moral responsibility to opt for avoidance, at least if the dis-
order in question is serious. Please note that this view does not justify
any legal constraints on reproductive decision-making.
Professional responsibilities
An offer of preconception ECS to patients applying for assisted repro-
duction raises particular ethical questions (that do not arise in other
PCS contexts) of professional responsibility. It is widely accepted that
professionals involved in assisted reproduction do not only have the
responsibility to assist couples in achieving a pregnancy; they are also
expected to take into account the welfare of the child that they are
causally and intentionally involved in creating. As stated by, amongst
others, the ESHRE Task Force on Ethics and Law, the physician must
take into account presently known risk factors for the welfare of the
future child (Pennings et al., 2007). Risk factors that may have implica-
tions for the welfare of the child include both medical conditions of
potential parents and psychosocial factors. To decide whether actual
risk factors are a valid reason for refusing assistance in reproduction,
ESHRE has recommended the ‘reasonable welfare’ standard. This stan-
dard entails a moral duty to refrain from providing assistance in cases
where there is high risk that the child will have a seriously diminished
quality of life. Moreover, above this bottom-line, professionals involved
are expected to limit health risks to the future child where doing so is
reasonably possible.
What follows from these professional norms with regard to offering
preconception ECS to patients seeking assisted reproduction? May (or
should) professionals recommend, or even insist, that patients one, un-
dergo preconception ECS, and two, make use of ‘preventative meas-
ures’ (PGT-M, gamete donation or prenatal diagnosis) when the
couple has been identified as a carrier couple? And how would such
professional ‘directivity’ relate to the above-discussed tension between
a couple’s reproductive autonomy and their parental responsibility?
Various scenarios (including a ‘mixed’ scenario) for the implementation
of a preconception ECS trajectory for patients seeking assisted repro-
duction can be distinguished based on either a non-directive offer with
the autonomy paradigm as the leading principle, or a directive offer
that considers the patient’s acceptance of this trajectory to be a pre-
condition for having access to assisted reproduction, taking into ac-
count professional and parental responsibilities for the welfare of the
future child (Fig. 1) (De Wert, 2016).
The implications of a non-directive offer are 2-fold. First, regarding
Step 1, it implies that patients should decide for themselves whether
they want to participate in the preconception ECS offered. A similar
line of reasoning applies to Step 2: the counselling trajectory should



















































..enable proven carrier couples to make a well-informed decision with
regard to reproduction. Whatever the couples decide, they will be as-
sisted in conceiving a child. The alternative directive policy implies,
firstly, that patients are expected to participate in this screening as a
precondition for assisted reproduction (Step 1). If patients turn out to
be a carrier couple, Step 2 implies that they will only have access to
assisted reproduction if they are prepared to substantially reduce the
risk of conceiving an affected child by means of ‘preventative meas-
ures’, to be further specified (see below).
Which policy is morally preferable? We recommend that for both
Steps 1 and 2 in the trajectory, this depends on first, the level of ge-
netic risk; and second, the severity of the disease under consideration
(in line with a former ESHRE-document on handling the risks of con-
sanguinity in the context of intra-familial medically assisted reproduc-
tion) (ESHRE Task Force on Ethics and Law et al., 2011).
Step 1: If patients seeking assisted reproduction have an a priori low
carrier risk, we suggest that preconception ECS should be offered only
in a non-directive way in order to facilitate autonomous reproductive
decision-making. This applies to most couples asking for assisted re-
production because of fertility problems. Some couples applying for as-
sisted reproduction may be at higher risk of being a carrier couple, for
instance because of ancestry: in the latter case, professionals may be
entitled to encourage these couples to participate in preconception
ECS. Imposing ECS as a precondition for access to assisted reproduc-
tion (a so-called ‘coercive’ offer), however, would be disproportionate,
as in absolute numbers, the risk of being a carrier couple of not yet
identified recessive disorders would still be very low. An illustrative ex-
ample is the incidence of TaySachs disease in the Ashkenazi Jewish
population. Compared with the general population, Ashkenazi Jews
are 10 times more likely to be carriers of this fatal disorder. In abso-
lute numbers, however, they have a carrier risk of 1 in 31, leading to a
risk of 1 in 961 of being a carrier couple, and a risk of only 1 in 3844
of giving birth to an affected child (Gross et al., 2008).
Step 2: Professionals may well justifiably recommend proven carrier
couples to consider preventative options, and even make access to as-
sisted reproduction conditional on the patients’ use of such options—
even though a ‘coercive offer’ entails a very directive approach. If we
follow the reasonable welfare standard, such conditional access may
be justified both in exceptional cases of disorders that would make life
intolerable for the child (e.g. TaySachs disease, Canavan disease,
Herlitz junctional epidermolysis bullosa), and with regard to conditions
that may not involve unbearable suffering, but nonetheless greatly re-
strict the range of life plans that humans typically value and choose,
and in general have a huge impact on the quality of life of affected per-
sons (e.g. CF and Usher syndrome).
Though PGT-M may well be the most evident preventative option
for many carrier couples, in practice people may prefer the use of do-
nor gametes or prenatal diagnosis instead, for example because PGT-
M is not reimbursed in their country and they cannot afford to pay
themselves. To insist, then, that carrier couples should make use of
PGT-M as a precondition for access to assisted reproduction would
be unjustifiably restrictive. Doctors involved in assisted reproduction
may feel unease when a carrier couple declines PGT-M and asks for
access to assisted reproduction with the intention to have prenatal
testing and termination of pregnancy in case of a ‘positive’ test result.
After all, this may generate a dilemma: should this wish be respected,
trusting that the couple will indeed try to avoid the birth of a seriously
handicapped child? Or should one abstain from giving access to assis-
ted reproduction, because couples may change their minds or even
betray the professional? Although there may be no single solution for
this dilemma, assisted reproduction in such carrier couples may well
be justified after extensive counselling. This opinion mirrors a former
ESHRE Opinion about a possible transfer after ‘failed PGT’, entailing a
similar dilemma (De Wert et al., 2014).
The above shows that, when there is a high genetic risk of serious
suffering, concerns related to the welfare of the future child may limit
Figure 1. Scenarios for a preconception expanded carrier screening trajectory for patients seeking assisted reproduction. ECS,
expanded carrier screening; PGT-M, preimplantation genetic testing for monogenetic diseases.
























































































the reproductive options available to carrier couples applying for assis-
ted reproduction. This also means that the aim of preconception ECS
to patients seeking assisted reproduction is somewhat mixed. When
the predicted level of well-being of the future child can be expected to
fall below the reasonable welfare standard, the professional involved
should make access to assisted reproduction conditional on the
patients’ use of preventative measures, as the alternative would be to
disregard professional and parental responsibilities. We suggest that
the preventative options created by new genomic testing possibilities
are not morally indifferent and may have implications for the opera-
tionalization of both parental and professional responsibilities. Instead
of ignoring these responsibilities, the screening and counselling process
should enable and motivate the involved parties to live up to them
(van der Hout et al., 2019).
Couples or individuals?
In the context of carrier screening for autosomal recessive disorders,
there is much discussion about how to report the test results to
patients: is it preferable to give them to the individual partners or to
approach couples as a ‘reproductive unity’? In the latter case, the re-
sult ‘screen-positive’ would imply that both individuals are identified as
carriers and ‘screen-negative’ that at least one individual is not identi-
fied as a carrier. Clarke is critical about couple testing as this would
entail that ‘couples in which only one individual is identified as a carrier
are not given that information’ (Harper and Clarke, 1997). These cou-
ples have nonetheless a greater residual risk of having an affected child
than couples in which none of the partners have tested positive.
Clarke furthermore states that ‘in general, tests should not be per-
formed if the results will be withheld from the individuals concerned’
(Harper and Clarke, 1997). Withholding this information would not
only restrict the reproductive autonomy of the individuals concerned
but would also deny members of a carrier’s extended family the op-
portunity to seek genetic counselling. However, if we consider that the
autonomy paradigm does not seek to enable reproductive choice per
se, but is aimed at enabling meaningful reproductive choices, reporting
individual test results might not be that obvious. Based on this qualifi-
cation, couple-based results of carrier screening for autosomal reces-
sive conditions are particularly relevant, as only carrier couples have a
greatly increased risk of 25% in each pregnancy that their child will be
affected. Furthermore, the additional costs of an individualized ap-
proach are considerable, especially when taking account of the need
for post-test counselling (see section ‘Justice’).
Proportionality
What about the proportionality of offering preconception ECS to
patients seeking assisted reproduction: do the possible benefits clearly
outweigh the possible harms?
Possible benefits
In the literature, it has been argued that universal ECS may be benefi-
cial for a variety of reasons. Many of these also apply to an offer of
preconception ECS to patients seeking assisted reproduction. Firstly, if
patients are informed about their positive carrier status, they can avoid
suffering of their future children and their own families by taking pre-
ventative measures. Moreover, if conducted in the preconception pe-
riod—which is necessarily the case in the context of assisted
reproduction—ECS may optimally provide patients with a diversity of
reproductive options and time for reflection. Clearly, this benefit pre-
sumes the provision of adequate information and counselling (see be-
low). Thirdly, informing blood relatives of carriers of their a priori
higher carrier risk may avoid suffering and facilitate informed reproduc-
tive choice. Finally, it has been argued that carrier screening may en-
able close prenatal and neonatal monitoring of possibly affected
children, thereby contributing to early detection and a better prognosis
(Henneman et al., 2016).
Possible harms and disadvantages
Commentators mention a set of highly different possible disadvantages
and risks of ECS. Some of these are societal or socio-cultural, in that
they regard possible risks for ‘wider society’ (‘socio-cultural harms’),
while another cluster of risks considers harms for the members of the
target group of ECS or, more specifically, the people participating in
the screening. No doubt, there is some overlap between these subsets
of risks.
Socio-cultural harms and disadvantages. Critics regularly seem to claim
that the first subset of risks of preconception ECS are prohibitive.
Possible societal risks include:
The ‘disability rights critique’. In fact, this is a cluster of arguments
including both the ‘expressivist’ argument, stating that the offer of such
screening entails a discriminatory message towards people affected
with the relevant disorders, and the ‘loss of support’ argument. The
latter argument suggests that if in the future the numbers of affected
people drop, the provision of adequate medical care and societal sup-
port for affected people may be undermined. The ‘expressivist argu-
ment’, however, arguably assumes that the dignity of people affected
with the diseases screened for would be undermined by reproductive
screening. This assumption is logically and empirically debatable, if not
unsound. The rights and citizenship of affected people are unlikely to
be denied. The ‘loss of support’ argument is, likewise, difficult to ac-
cept. First, the opposite claim can be made that more resources will
be available for fewer patients, which will result in better care. Second,
we would not claim that it is desirable to have more people with cur-
rently rare diseases, merely to heighten the degree of support. Third,
this argument is inconsistent with other practices, such as the recom-
mendation that prospective mothers take folic acid to prevent neural
tube defects (Buchanan et al., 2001). Thus, while the concern of loss
of support is a societal point of attention as we move forward, it is
not a counterargument against ECS.
The ‘medicalization critique’. Some critics consider carrier screening
to be just another example of problematic medicalization of reproduc-
tion. Medicalization, however, is a ‘moral species’ term; it is important
to unravel the argument to clarify what this objection really entails. It
is difficult to reject the medicalization of reproduction if and insofar as
this would prevent serious suffering and handicaps in future children
and families. The medicalization critique is often inspired by the so-
called ‘social model of disability’, which points to the societal origins of
suffering linked with medical impairments—think of widespread stigma-
tization, discrimination and exclusion. But while environments should
be adapted wherever possible, and ‘inclusion’ is a laudable aim, many
genetic diseases and handicaps are linked with disadvantages and suf-
fering which cannot be entirely eliminated, even in an ideal society
(Shakespeare, 2013). Furthermore, the force of this objection seems
to be especially weak when preconception ECS is offered to patients
























































































seeking assisted reproduction, who are already seeking reproductive
help from medical doctors.
The objection in terms of eugenics. Like medicalization, eugenics is a
‘moral species term’ which may have many different meanings (Paul,
1994). It is difficult to condemn the avoidance of conceiving children
affected with serious disorders insofar as this would prevent serious
suffering. Problematic eugenic practices typically regard involuntary
measures (think of forced sterilization). Clearly, the dominant frame-
work for both prenatal screening and universal ECS—stressing the im-
portance of reproductive choice—seems to be less vulnerable to the
objection in terms of ‘eugenics’, at least as long as the screening offer
concerns the identification of risks for highly penetrant diseases that
severely affect the offspring. The same applies for the somewhat more
ambiguous framework of preconception ECS in assisted reproduction:
it would be simplistic and rhetoric to disqualify a professionals’ decision
to only conditionally assist in the reproduction of carrier couples at
(very) high risk of having a child with a serious genetic disease as ‘eu-
genic’. Respect for reproductive autonomy should be qualified as it
does not oblige doctors involved in reproductive medicine to disregard
their professional responsibilities to take account of the welfare of fu-
ture children.
To conclude, the possible societal risks of carrier screening do not
seem to constitute an overriding objection to preconception ECS in
assisted reproduction (nor to universal ECS). This should not be a sur-
prise, as it would be inconsistent to accept prenatal screening for con-
genital disorders like Down syndrome and neural tube defects if this
meets internationally endorsed screening criteria and at the same time
categorically condemn ECS based on these general (non-specific) soci-
etal risks.
Individual harms and disadvantages. The second class of risks regards in-
dividual harms and disadvantages. These include the following.
Reproductive dilemmas. Firstly, ECS may confront prospective
parents, and especially carrier couples, with difficult reproductive deci-
sions and even dilemmas. However, this may be seen as the price to
be paid for facilitating ‘informed reproductive choice’. Probably, many
prospective parents will agree that it is better to be informed of a
repro-genetic risk you wish to avoid, than being spared of this informa-
tion and assuming the risk you want to avoid unknowingly. But clearly,
the present concern underlines the general prerequisite regarding the
provision of adequate pre- and post-test counselling in the context of
any reproductive screening. In the context of assisted reproduction,
some PGT-M patients may be faced with especially complex dilemmas:
if preconception ECS reveals additional genetic risks—apart from the
genetic risk that triggered them to apply for PGT-M in the first
place—their dream of having unaffected children may be seriously
threatened or even fall apart.
The current risk may be differentiated by taking into account the
screening test per se. General criteria to evaluate screening tests have
been provided in, amongst others, the so-called Analytic validity,
Clinical validity, Clinical utility and Ethical, legal and social issues
(ACCE) framework. The ACCE process includes collecting, evaluating,
interpreting and reporting data on particular genetic tests, allowing pol-
icy makers to have access to up-to-date and reliable information for
decision-making (https://www.cdc.gov/genomics/gtesting/acce/index.
htm). The tests used should have high analytical and clinical validity
and good clinical utility. Analytical validity is defined as the test’s ability
to accurately and reliably measure the relevant genotype. Clinical valid-
ity is defined as the test’s ability to detect or predict the associated
handicap or disease. Clinical utility refers to the value of the informa-
tion generated by the test for medical practice. For ECS, clinical utility
has been specified by the European Society of Human Genetics as ‘the
increase in a couple’s reproductive autonomy and choice’ (Henneman
et al., 2016). Obviously, screening test characteristics are highly rele-
vant for the evaluation of any screening programme, also because of
their implications for the possible proportionality of screening; if the
test used has a low analytical and clinical validity and/or a low clinical
utility, this will seriously undermine the proportionality of the screen-
ing. A detailed operationalization of these criteria for preconception
ECS in assisted reproduction is beyond the scope of this document. A
few remarks about the test’s clinical validity and utility and its relevance
for the evaluation of such screening’s proportionality should suffice for
the moment.
Many genetic disorders show the so-called ‘allelic heterogeneity’,
meaning that various or even many sequence variants in the relevant
gene may be linked with the disease at hand. The best example may
be the CF transmembrane conductance regulator (CFTR) gene, linked
with CF, which shows more than 2000 variants (Sosnay et al., 2013;
Pereira et al., 2019). Exact data about so-called ‘genotype-phenotype
correlations’ are usually not available, and these correlations (may) dif-
fer in different ethnic populations. Obviously, this may create uncer-
tainty, and, thus, psychological, and decision-making problems in
screened individuals/couples, in different ways. Firstly, it is not always
clear as to whether a given variant is linked with either a serious or a
milder phenotype—some variants may even generate both mild and
serious phenotypes. Secondly, the test may generate variants of un-
known clinical significance (VOUS). In view of these variables, a choice
has to be made between different scenarios:
• ECS should be targeted to serious and well-understood variants.
• ECS may, in addition, include variants with a variable (serious or
mild) expression.
• ECS may even include variants (always) correlated with a mild
phenotype.
• ECS may include VOUS as well.
If one opts for the first, most targeted strategy, the numbers of
false negatives, resulting in false reassurance, will increase. Especially
milder disease-causing and rare variants may, then, not be detected.
If one opts for the last, most inclusive strategy, the number of
VOUS will increase (Abuli et al., 2016). Considering the responsibil-
ity of fertility clinics offering preconception ECS to guarantee pro-
portionality, the experimental character of such screening and the
possible huge impact on a couple’s welfare and reproductive
decision-making, a cautious approach is warranted, at least for the
time being. Some of the implications for the handling of milder var-
iants and variants with a variable (mild or serious) expression will be
addressed in the next section. In order to avoid psychological stress
and decision-making problems linked with VOUS, clinicians offering
preconception ECS to patients seeking assisted reproduction are ad-
vised only to report class 4 and 5 variants, i.e. variants that are likely
or definitely pathogenic.
If ECS generates VOUS, it is widely—and rightly—accepted to pref-
erably store these findings in databanks, in order to allow their inclu-
sion in research aimed at clarifying genotype-phenotype correlations.
























































































In view of such research, later re-classification of test results may be
necessary, for example from (presumed) pathogenic to benign, from
VOUS to non-pathogenic, or from VOUS to pathogenic. This would,
then, raise issues about re-contacting the couples. The implications of
such storage and re-contacting for counselling and informed consent
will be touched on below (Edwards et al., 2015; Vaz-de-Macedo and
Harper, 2017).
While there is concern that proven carrier status may have adverse
psychological consequences, like increased distress, various studies
suggest that this is not a serious risk (Lakeman et al., 2009; Holtkamp
et al., 2016). However, very little is known about the psychological im-
pact of ECS, especially if this would identify people/couples as carriers
of more than one recessive disorder.
Impact of health risks for carriers. Depending on the disorders in-
cluded in the screening panel, carrier status may entail risks for later-
onset disease or impairment in carriers themselves. This, for instance,
regards female carriers of a pre-mutation (PM) for Fragile X syndrome
(FXS); these women are at increased risk for both premature ovarian
insufficiency (POI) and the Fragile X-associated Tremor/Ataxia
Syndrome (FXTAS, a neurodegenerative disorder) (European Society
for Human Reproduction and Embryology Guideline Group on POI
et al., 2016). Such risks raise questions about the proper scope of, and
conditions for, a responsible offer of preconception ECS in the context
of assisted reproduction (see below).
Stigmatization and discrimination. A third risk regards (social) stigma-
tization and discrimination of carriers/carrier couples. Although grow-
ing awareness of the fact that ‘we are all fellow mutants together’
(Muller, 1950) may help to reduce the risk of genetic stigmatization,
there are still some concerns. Discrimination was a manifest effect of
early carrier screening for sickle cell disease (SCD) in the USA. Some
insurance companies refused to accept carriers of SCD, wrongly as-
suming that (heterozygous) carriers were (homozygous) patients suf-
fering from SCD (United States. President’s Commission for the Study
of Ethical Problems in Medicine, 1983). Private health insurance com-
panies might consider not reimbursing the treatment of and care for
handicapped children whose existence could have been prevented by
parents informed about their genetic risk. Clearly, such discriminatory
policy would not just undermine reproductive autonomy but would
also entail a grave injustice towards these children who would, then,
often be deprived of adequate treatment and care. With regard to
possible social stigmatization, ethnic stereotyping has been mentioned
as an adverse effect of some older carrier screening programmes in
the USA, targeted at the black community (United States. President’s
Commission for the Study of Ethical Problems in Medicine, 1983).
Universal ECS may well be an effective way to counteract such ethnic
profiling.
The mostly reassuring findings regarding possible stigmatization of
carrier screening so far relate to screening of fertile prospective
parents. These findings, however, may not be entirely applicable to an
offer of preconception ECS in the context of assisted reproduction. A
recent large-scale survey has revealed that, ‘despite the increased
awareness of infertility and emergence of new technologies increasing
treatment success, infertility stigma persists, particularly for women’
(Slade et al., 2007; Ergin et al., 2018; Worthington et al., 2019).
Couples applying for assisted reproduction because of infertility prob-
lems may feel even more stigmatized if they turn out to be carriers of
the same recessive disorder.
All in all, whereas there is no consensus regarding the proportional-
ity of universal preconception ECS, a screening offer specifically
addressing patients seeking assisted reproduction might, as some pro-
ponents suggest, more easily meet the proportionality criterion. After
all, members of the target group are already seeking medical assistance
in reproduction and may be very willing to at least seriously consider
the uptake of such screening. Furthermore, this medical context may
well facilitate the provision of adequate information and counselling
(see below). But even though this may seem to be a reasonable as-
sumption, a firm conclusion regarding the proportionality of precon-
ception ECS in assisted reproduction is premature, as there are many
open questions that require further scrutiny, reflection and research
(see below).
The scope of preconception ECS in
assisted reproduction
As has been mentioned in the Background section, carrier screening
was traditionally targeted to one or just a few genetic conditions. NGS
technologies enable people to screen for carrier status of many condi-
tions simultaneously—even whole exome/genome sequencing and
analysis (WESA/WGSA) has become possible and increasingly afford-
able in recent years. New technologies, however, bring new challenges
and problems.
Companies offer ‘direct to consumer’ genome-wide screening pack-
ages, also for PCS (Borry et al., 2011), which seems to be strongly
technology-driven and commercially motivated. Obviously, this prac-
tice, which is not accompanied by proper counselling, does not define
the standard of professionals offering ECS in healthcare. What, then, is
the appropriate scope of preconception ECS in assisted reproduction?
Focus on serious congenital and childhood diseases
As the major aim of the screening is to provide prospective parents
with meaningful reproductive information, the dominant view is that
the analysis should be targeted; whole exome/genome analysis would
simply result in information overload, undermine reproductive confi-
dence, and distort the balance between possible benefits and harms/
disadvantages of reproductive genetic screening generally and ECS par-
ticularly (Dondorp et al., 2015). But how, then, to target the analysis?
There seems to be a strong consensus that ECS should primarily focus
on (both autosomal and X-linked) recessive, serious, congenital and
childhood diseases (Henneman et al., 2016). This focus is in-line with
traditional (ancestry-based) carrier screening and seems to be reason-
able, though it needs some justification and specification—and might
have a provisional character.
A focus on serious conditions probably best meets prospective
parents’ reproductive concerns linked with having an affected or po-
tentially disabled child and reproductive doctors’ responsibility to avoid
a ‘high risk of serious harm/suffering’. The specification that the seri-
ous disorders screened for should be primarily congenital and child-
hood disorders, follows the same rationale. The criterion of
seriousness is, however, notably difficult to define (Wertz and
Knoppers, 2002). Even if people agree about the relevance of this cri-
terion, they regularly disagree about how this should be made opera-
tional, and, consequently, may have diverging views about what to
include in the screening package. This is not to suggest, however, that
any operationalization and demarcation of ‘serious’ is purely subjective
























































































and arbitrary. It should be possible to reach some inter-subjective
agreement about (the operationalization of) relevant criteria—though
there will always be a grey area, where reasonable people may dis-
agree. Recessively inherited blindness and deafness may be good
examples of this grey area. General criteria for seriousness, to be fur-
ther re-fined, include a lower life expectancy, intellectual disability, im-
paired mobility, a substantial adverse impact on ‘normal functioning’,
the need for (a series of) surgical interventions—especially if these are
only partly effective—and regular hospitalization, or, more generally,
an adverse impact on children’s quality of life (Lazarin et al., 2014;
Edwards et al., 2015). Both the expertise of professionals, especially
professionals engaged in traditional genetic counselling and paediatrics,
and the lived experience of families with affected children may well
give (experiential) input to further debates about the precise content
of the screening package focused on serious (congenital and child-
hood) disorders. This content may need continuous updating taking
into account findings of such studies and progress in medical science
(Capalbo et al., 2019; Kaseniit et al., 2019; Weisz-Hubshman et al.,
2019; Fridman et al., 2020). The inclusion of the patient perspective is
crucial in order to avoid any medical bias and one-dimensionality.
Adding to the complexity of the current issue is allelic heterogeneity
(see above). Genetic variants that are associated with a milder expres-
sion of disorders that are, generally, classified as serious, should prefer-
ably not be included in ECS that focuses on serious disorders. But
would it be acceptable to include genetic variants with a variable ex-
pression, generating either a serious or a mild phenotype? One could
argue that by including such variants the thin line to disproportionality
would be easily transgressed, also because this more permissive
screening policy would invite complex ranking of ‘affected’ embryos
for transfer—unless the clinic sticks to a policy to never transfer an af-
fected embryo, even if embryos carrying such variants do not neces-
sarily result in children affected with a serious disorder. But one could
also argue that the inclusion of such variants would not necessarily un-
dermine the proportionality of ECS—on the contrary, it could even in-
crease its proportionality, also by facilitating better embryo ranking.
Whatever the outcome of this balancing, the clinic’s handling of genetic
variants with a variable expression should be addressed in pre-test
counselling (see below).
Symptomatic of the threat of a technological imperative—referring to
the idea that emerging technologies are inevitable and must be em-
braced—is not just the risk that carrier screening will be ‘maximally ex-
panded’ without evidence of its proportionality, but also that ECS
panels ‘often include conditions for which carrier screening of the gen-
eral population is not recommended by current practice guidelines’
(Edwards et al., 2015). A good example is the inclusion of FXS. In the
grey area of PMs, the risk of expansion to a full mutation (FM) may be
difficult to predict. Furthermore, the phenotype—especially the possible
intellectual disability—of future daughters with an FM is notably difficult
to predict. And last but not least, as said, female PM carriers are at
high risk of both POI and FXTAS, blurring PCS and pre-symptomatic
diagnosis of late(r)-onset disorders (Grody, 2016; Willemsen and Kooy,
2017). This is not to say that carrier screening for FXS is necessarily un-
sound, but it illustrates the complexities involved.
The challenge, then, is to make sure that specific disorders are only
included in any ECS panel—either offered to the general population or
particularly addressing patients seeking assisted reproduction—if this
seems to be proportionate, given the available evidence.
Smaller-scope ECS?
Various arguments may be proposed to limit the scope of ECS,
including:
Firstly, one might argue that disorders which are included in new-
born screening (NBS) need not be included in/should be excluded
from the screening panel. Think of, for example, SCD and CF. This cri-
terion is, however, debatable and would limit the scope of ECS for no
good reason, in view of the different aims of these screening pro-
grammes. While NBS primarily aims at early detection and timely
treatment of affected new-borns, in order to improve their prognosis,
ECS serves informed reproductive decision making of prospective
parents. For those NBS conditions (inborn errors of metabolism)
where affected infants may die before the NBS result is communi-
cated, or where part of the health damage involved cannot be avoided
after NBS, it could be proportionate to also add the condition to the
ECS panel (Kirk et al., 2020). These programmes should, then, be con-
ceived of as complementary (Wilfond, 2009). The existence of NBS
does not render ECS unsound or unnecessary.
Secondly, the scope of ECS should, some argue, be limited to the
availability of and eligibility to (i.e. indications accepted for) PGT-M in
the given jurisdiction. Clearly, ‘patients should not embark on ECS un-
der the belief that the option of PGT-M will be unquestionable in light
of a positive result’ (Vaz-de-Macedo and Harper, 2017). But although
the composition of ECS panels should ideally be linked to the availabil-
ity of PGT-M for the same disorders, we doubt as to whether the first
should be necessarily limited to the latter. First, a broader composition
of the ECS panel could be a catalyst for widening the eligibility to
PGT-M in more restrictive jurisdictions.
Secondly, even if PGT-M is not available for a subset of serious con-
ditions in particular jurisdictions, ECS including these conditions could
still facilitate informed reproductive choice (though, more limited) by
either offering other types of reproductive avoidance (for instance, do-
nation and adoption) or by carrier couples’ willingness to seek PGT-M
abroad. Clearly, this needs further debate.
Broader-scope ECS?
Obviously, one may also consider broadening the ECS panel, and in-
clude, for example disorders manifesting a different inheritance
pattern.
One could include, for instance, (selected) autosomal dominant
(AD) disorders (as some programmes do), focussing mostly on early
onset AD disorders (Abuli et al., 2016), e.g. autosomal dominant poly-
cystic kidney disease (Gimpel et al., 2019) or possibly Alexander dis-
ease (Battaglia et al., 2019), but maybe also late onset AD disorders,
like Huntington’s disease (HD), ‘early-onset’ dementias, and some he-
reditary cancer syndromes. As for any (widening of a) screening pro-
gramme, the prerequisite of proportionality is of paramount
importance. Importantly, the possible benefits of such wider ECS panel
may be less clear, as higher penetrance AD disease-causing variants
will often be already known among the members of seriously affected
families (generating an indication for pre-symptomatic diagnosis in rela-
tives of the probands). Furthermore, such widening of the scope of
ECS may have serious disadvantages and drawbacks, for various rea-
sons. To mention just a few: this would blur ECS and pre-
symptomatic testing for late-onset disorders, informing patients about
genetic health risks for both their possible children’s and for their own
future health, generating additional concerns and anxieties. Some
























































































disease-causing variants for later-onset disorders are ‘actionable’ (in
the traditional meaning of enabling primary/secondary prevention for
the benefit of the carrier), others are not—but may still be relevant
for carriers’ reproductive decision-making. Clearly, the meaning and
mixing up of two types of ‘(non-) actionable’ may be confusing for
many people. Furthermore, the penetrance of AD disease-causing var-
iants in the general population may be lower than the penetrance of
such variants in affected families. This may, paradoxically, increase the
emotional load of testing for such variants.
Secondly, one could consider adding mitochondrial (mt) disorders
that are maternally transmitted caused by disease-causing variants in
mtDNA to the ECS panel. Given the existence of an early germline
bottleneck, currently carrier screening for such disorders may have
only very limited value (Marchington et al., 2010) Again, such widening
would add practical difficulties and complex counselling issues. Think
particularly of the lower predictive value of relevant mtDNA variants
and the limited value and availability of reproductive options like PGT,
prenatal diagnosis and—highly experimental—mitochondrial replace-
ment therapy (Hallowell, 2012).
In view of this, broader-scope ECS (including carrier screening for
late-onset diseases and for disorders caused by variants in mtDNA) is
currently not considered the best option. There are simply too many
uncertainties and unknowns. Restricting ECS to serious AR congenital
and childhood disorders has the largest chance to be proportional for
the moment.
A linked question for further debate is whether and, if so, on what
conditions, it would be sound to offer ‘personalized’ preconception
ECS to patients seeking assisted reproduction, allowing them to deter-
mine (or at least engage in shared decision making regarding) the
scope of their ‘personal’ ECS panel. Though such personalization may,
at least in theory, be in line with the principle of respect for (reproduc-
tive) autonomy, one of the questions to be addressed is how informed
consent models could be developed that can be adequately made op-
erational in clinical practice without undermining the quality and legal
validity of the counselling.
Justice
From a justice perspective, various types of considerations are impor-
tant, including the examples below.
In terms of economy, are the so-called ‘opportunity costs’ of repro-
ductive genetic screening—generally and of preconception ECS in as-
sisted reproduction particularly—justified, especially when considering
the just distribution of scarce resources for healthcare? A similar ques-
tion is raised with many other provisions in healthcare, including assis-
ted reproduction itself. Lack of funding will result in inequity. With
restricted budgets, however, some ‘prioritization’ seems to be un-
avoidable. Still, in view of the importance of reproductive screening (at
least partial) funding may be considered, in principle, insofar as such
screening may help to prevent serious suffering, facilitates ‘just choices’
(Stapleton et al., 2019) and meets relevant capabilities (Nussbaum,
2011). Even though the primary aim of any reproductive genetic
screening is not to reduce healthcare costs (see before), the fact that
ECS may, in fact, save money in the long run that could be used to
meet other healthcare needs, is a relevant factor to be taken into ac-
count in the calculus.
One needs to also consider justice with respect to equity.
Obviously, there is not one single carrier screening practice or policy
in Europe. Two types of situations may be distinguished:
• In some countries, targeted PCS is already ‘universally’ offered to
the public. The best example may be Cyprus, where all prospec-
tive parents are offered carrier screening for haemoglobinopathies
at the premarital stage. In those countries, the principle of equity
requires that both (fertile) couples engaging in sexual reproduction
and couples applying for assisted reproduction (either for reasons
of subfertility or for genetic reasons) receive the offer of (targeted
or expanded) carrier screening. The main question to be
addressed, then, is whether the moral framework for carrier
screening in these two different contexts is the same or not.
• Most countries do not (yet) offer any type of carrier screening, let
alone ECS. Would a selective offer of preconception ECS to
patients seeking assisted reproduction, then, be justified—taking ac-
count of the equity requirement? Would it be sound to selectively
offer ECS to this subgroup, while all other prospective parents
have the same a priori risk? Some may argue that this would be at
odds with formal justice and the non-discrimination principle, as
similar cases should be treated similarly. But one may argue that
there are relevant differences that may justify differential treat-
ments. Firstly, professionals involved in assisted reproduction carry
responsibilities regarding both the optimization of treatment and
the welfare of the possible future child. A second argument could
be that selective ECS for patients seeking assisted reproduction
more easily meets the proportionality requirement (than universal
ECS), in that these patients are already in the process of assisted
reproduction (often IVF, sometimes even IVF/PGT-M), and ade-
quate counselling may be easily guaranteed. If one does not con-
sider these arguments to be convincing, a selective offer of
preconception ECS to patients seeking assisted reproduction might
still be—albeit just temporarily—justified as part of a learning tra-
jectory towards possible future, universal, implementation of ECS.
Obviously, we must be cautious about ‘upselling’ lucrative genetic
screening to patients who are in a somewhat vulnerable position
towards their fertility doctor/clinic. Patient interest, not commercial
interest, should determine clinical care. As indicated, the physician’s
responsibility for the welfare of the future child should not be used
as a rhetorical tool to prematurely implement experimental ECS in
assisted reproduction as a self-evident, routine strategy, let alone
to make ECS obligatory for all patients.
Informed consent and the art of
counselling
Informed consent and counselling are primarily instruments to make
respect for autonomy operational. Though intertwined, the two are
not the same; while the information to be provided regards the rele-
vant (medical) facts and procedures, counselling aims at helping cou-
ples to make a decision, first and foremost by linking the relevant facts
with their personal needs, values and preferences.
When it comes to the definition of good clinical practice generally
and adequate informed consent particularly, clinicians should always
take account of the relevant legal norms in their countries’ jurisdic-
tions. From an ethical point of view, general requirements are that the
























































































information provided is adequate and that the consent solicited is
voluntary.
Two requirements are especially important when it comes to the
provision of information. First, especially in the context of a screening
trajectory, the provision of information and counselling is not one sin-
gle event, but a process, taking account of both the whole trajectory
and the specific step at hand (Health Council of the Netherlands,
2001). In the context of the preconception ECS trajectory, at least
three steps/moments can be distinguished: first, the offer of and deci-
sion about participating in the screening; second, the offer of and deci-
sion about reproductive options for carrier couples identified by the
screening; and, third, if a carrier couple participates in PGT-M and the
embryos prove to be affected, the offer of and decision about the
options then available, including: no transfer (and possibly the start of
another IVF-ICSI/PGT-M cycle) and, possibly, ranking (Human
Fertilisation and Embryology Authority (HFEA), 2019).
A second aspect regards the so-called standard of disclosure. The
‘reasonable person’ standard, which defines what reasonable persons
generally need to know in order to be able to make an informed deci-
sion, should be used as the initial standard of disclosure. This standard
has to be supplemented by the ‘subjective’ standard, which judges the
adequacy of information by reference to the specific informational
needs of the individual person (Beauchamp and Childress, 2013). The
individual or couple seeking screening should, then, always be invited
to bring their questions and concerns. Consequently, the informed
consent process should, at least partly, have the character of a
dialogue.
Clearly, the information to be provided, like the issues to be
addressed in related counselling, is highly dependent on the content
and scope of the screening offered. The wider the scope of the
screening, and the more comprehensive the categories of variants one
wants to communicate (including variants with a variable expression
and VOUS), the more challenging it will be to obtain people’s truly in-
formed consent. Without suggesting an exhaustive list for the provision
of adequate information and counselling at each of the moments in
the process, the points to consider include the following:
Firstly, regarding ECS per se: as a starter, the professional should briefly in-
troduce this option and ask the patients whether they want to know more
about this screening. If so, the professional may then give some more infor-
mation and offer counselling.
Clearly, it is not practical for a clinician to clarify and discuss each
disease included in multi-disease screening panels in detail (Grody
et al., 2013). The implication of offering ECS must, then, be that some
sort of ‘generic consent’ is implemented. Even though such generic
consent may be morally justified (as ‘good enough’), some complex
questions need further reflection, most importantly: how to guarantee
that generic consent is being made operational as a (reasonable)
variant of informed consent—not as a (problematic) alternative for
informed consent?
While it is sometimes suggested (Edwards et al., 2015) that informa-
tion about carrier couples’ reproductive options can and should be
postponed and be given in the context of post-test counselling, this
information should—though roughly—be provided in the context of
pre-test counselling, like global information about professional responsi-
bility for the welfare of the future child and decision-making authority
regarding the handling of possibly affected PGT-embryos. Likewise, the
possible relevance of the findings of ECS for relatives, and the clinic’s
policy regarding the handling of possible ‘conflicts of duties’ should be
ticked off in pre-test counselling.
In view of both the lack of experience of patients with the genetic
disorders included in the ECS panel and the complexity of this screen-
ing, it is to be expected that a sound offer of ECS will require substan-
tial counselling facilities—with substantial logistic and financial
implications (cf. the section on Justice). It should not be assumed that
an adequate level of understanding ‘can be achieved quite easily for
couples that ask for pregestational genetic counselling and for those
that are in the process of ART’ (Abuli et al., 2016). Importantly, the
majority of patients have a fertility problem (not a genetic problem),
and although the subset of couples that apply for PGT-M will expect a
discussion of their genetic situation, they will probably not expect the
offer of preconception ECS for totally different genetic problems.
Especially members of the latter subgroup may sometimes be con-
fronted with a combination of genetic problems, generating an indica-
tion for ‘combination’ PGT-M, i.e. PGT-M for both the original
indication and, simultaneously, for the disorder identified through ECS
(Dondorp and de Wert, 2019). This may culminate in a situation in
which all embryos tested with PGT-M will prove to be affected, even
more so if PGT-M is combined with aneuploidy screening (PGT-A; for-
merly termed preimplantation genetic screening (PGS) for aneuploidy)
or if PGT-M is based on so-called haplarithmisis, which may simulta-
neously identify (selected) aneuploidies (Masset et al., 2019). The
wider the scope of PGT, the higher the risk that couples will have no
child at all.
An important part of the information provided regards their a priori
risk of having a child affected with a condition included in the ECS-
panel and expectation management; patients may wrongly assume that
ECS guarantees the birth of a healthy child. Clearly, ‘risk-free’ repro-
duction is an illusion, even in the era of reproductive genomic medi-
cine. There is always a residual risk, in various ways; even ECS will
focus on just some categories of disorders and on just a subset of var-
iants (possibly) linked with the disorders included in the screening
panel.
As said, though some personalization of ECS may, at least in theory,
be in line with the principle of respect for (reproductive) autonomy,
further debate and research is needed to determine how informed
consent models aimed at personalization could be developed that can
be adequately made operational in clinical practice.
Secondly, carrier couples identified need to be informed and coun-
selled in more detail about the reproductive options available.
Regarding PGT-M, especially possible tensions linked with the decision
making authority about the (non-)transfer of affected embryos need
closer attention. Likewise, the implications of patients’ proven carrier
status for relatives will be a more pertinent part of the agenda now,
especially when a woman proves to carry an X-linked disease.
Thirdly, when preimplantation embryos prove to be affected with a
disorder included in the ECS panel, detailed counselling is crucial. This
will generally regard primarily the ‘pros and cons’ of a possible addi-
tional IVF-ICSI/PGT-M cycle and the possible donation of affected em-
bryos for research purposes. In some situations, there may be
additional issues to be counselled in detail, especially when preimplan-
tation embryos are shown to have a milder anomaly, for example, a
milder variant of a serious disorder screened for, or a milder chromo-
somal aberration detected via haplotyping or via additional PGT-A, like
























































































47, XXY (Klinefelter’s syndrome). Additional counselling may also be
required when embryos have an unclear risk status, for example after
PGT-failure (when PGT does not generate a diagnosis), when the em-
bryo carries genetic variants with a variable expression, or when sup-
plementary PGT-A shows an embryo to have an autosomal trisomy,
like trisomy 21, with a mitotic origin. In such cases, ranking embryos
for transfer may be considered, depending on the harm/probability-
ratio in given cases. An in-depth reflection on (counselling issues linked
with) ranking is beyond the scope of the document.
No doubt, research on informational and counselling needs and on
the adequacy of information and counselling provided in the context
of each of these steps in (pilots for) ECS is crucially important. The
same holds true for the role and (implicit) value judgements of algo-
rithms used for ranking.
Conclusions and
recommendations
When considering or providing preconception ECS to patients seeking
assisted reproduction, clinicians should always take account of relevant
medico-legal norms in their countries’ jurisdictions.
Presumed ‘categorical’ ethical objections to preconception ECS in
assisted reproduction are not convincing. Such screening may well be
morally justified, if and insofar as it meets the proportionality criterion.
A firm conclusion regarding the proportionality of preconception
ECS in assisted reproduction is premature, as relevant genetic, epide-
miological, economic and especially psychological data are lacking.
There are many open questions that require further scrutiny, reflection
and research, including for instance the interest in screening of couples
seeking assisted reproduction, their reproductive choices after ‘posi-
tive’ results, the impact of screening on their welfare, the impact of
possible tensions between a doctor’s professional responsibility and
the reproductive autonomy of patients, the scope of the screening
panel, etc.
It is crucial that preconception ECS in assisted reproduction is em-
bedded in rigorous research protocols with appropriate reporting.
Furthermore, education of the public, as well as of medical students
and professionals will be needed after research outcomes have be-
come available. The ‘evidentiary’ model (Wilfond and Nolan, 1993)
requires adequate pilot studies and continuous monitoring and evalua-
tion (Edwards et al., 2015).
According to the dominant view, the primary aim of universal carrier
screening—i.e. a targeted or ECS offer to the general population—
should be to facilitate reproductive choice. The aim of preconception
ECS in assisted reproduction, however, is mixed in view of the dual re-
sponsibility of doctors involved in assisted reproduction. While the
screening offer itself should be non-directive, it is good clinical practice
to give carrier couples of serious disorders—i.e. those that do not
meet the ‘reasonable welfare’ standard as accepted by ESHRE—access
to assisted reproduction only on condition that they opt for ‘avoid-
ance’ and apply for PGT-M, donor gametes, or, maybe, prenatal
diagnosis.
Preconception ECS in assisted reproduction should preferably be
limited to recessive, serious, congenital and childhood disorders and to
class 4 and 5 variants linked with these disorders, at least to start
with. A possible broadening of the scope of preconception ECS in as-
sisted reproduction requires adequate research and interdisciplinary
debate.
The proper operationalization and feasibility of generic consent in
preconception ECS in assisted reproduction needs further debate.
Counselling should always be offered. It should not take a back seat,
as adequate counselling is a necessary condition for guaranteeing the
proportionality of preconception ECS in assisted reproduction. To en-
able couples applying for assisted reproduction to make a well-
informed decision about participating in ECS, information about carrier
couples’ reproductive options, taking account of professional responsi-
bilities, should already be provided in the context of pre-test
counselling.
A facilitating and co-ordinating role of ESHRE regarding research
and reflection aimed at the development of evidence-based, responsi-
ble guidelines on preconception ECS in assisted reproduction is highly
recommended. This should include minimum requirements regarding
clinical and analytical validity and the refinement of criteria to deter-
mine the scope of ECS.
The current recommendations should be evaluated periodically, also
taking account of new reproductive options that may become available
in the years to come, notably non-invasive prenatal diagnosis (NIPD)
very early in pregnancy and germline genome editing.
Disclaimer
This Ethical document represents the views of ESHRE, which are the
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